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Purpose: Vascular endothelial growth factor (VEGF) is one of the most important growth factors for metastatic tumors. To clarify the role 
of VEGF-A and C in patients with peptic ulcer disease (PUD) or gastric cancer (GC), we evaluated the expression levels of these two mol-
ecules. We also analyzed the effect of Helicobacter pylori infection on VEGF-A and C expression levels.
Materials and Methods: Patients with dyspepsia who needed diagnostic endoscopy were selected and divided into three groups: non-
ulcer dyspepsia (NUD), PUD, and GC, according to their endoscopic and histopathological results. Fifty-two patients with NUD, 50 with 
PUD, and 38 with GC were enrolled in this study. H. pylori infection was diagnosed by the rapid urease test. After RNA extraction and 
synthesis of cDNA, the expression levels of VEGF-A and C were determined by quantitative reverse transcriptase polymerase chain reac-
tion.
Results: The VEGF-C expression level in the PUD and GC groups was significantly higher than that in the NUD group. Moreover, the 
VEGF-A expression level in the PUD and GC groups was higher than in the NUD group, although the differences were not statistically 
significant. Significant positive correlations were also observed between the expression levels of these two molecules in the PUD and GC 
groups. In addition, the expression levels of these two molecules were higher in H. pylori positive patients with PUD or GC than in H. 
pylori negative patients of the same groups; however, these differences did not reach statistical significance.
Conclusions: Up-regulation of VEGF-C expression during gastric mucosal inflammation may play a role in the development of peptic ul-
cers or GC.
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Introduction
Dyspeptic disorders such as gastroesophageal reflux, gastritis, 
peptic ulcer disease (PUD), and gastric cancer (GC) are major 
medical conditions.1 PUD is usually associated with a reduced 
health-related quality of life, whereas GC is the fourth most com-
mon cancer and the second leading cause of cancer-related deaths 
worldwide.2,3 Host factors such as genetics and nutrition, and en-
vironmental factors such as Helicobacter pylori infection may be 
involved in the development of these conditions.1,4
H. pylori infection has been shown to be a major risk factor 
for the development of PUD and GC.5,6 However, despite several 
investigations, it is still not completely understood why the major-
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ity of infected people (80%~90%) carry and spread the bacterium 
while they are asymptomatic, or why only a small percentage of 
infected people develop peptic ulcers, whereas others develop GC.6
Host immune responses against H. pylori can result in chronic 
inflammation in the gastric mucosa, which in turn leads to the de-
velopment of pathological conditions including PUD and GC.5,6
Vascular endothelial growth factors (VEGFs) are glycopro-
teins secreted by tumor cells that are the most important factors 
in angiogenesis and tumor metastasis.7 The VEGF family includes 
VEGF-A to F and placental growth factor.7,8 Studies have shown 
that VEGF-A and B play a key role in blood vessel growth, 
whereas VEGF-C and D are important for the growth of lymphat-
ic vessels.9,10 The role of VEGFs, particularly VEGF-A, C, and D 
in promoting angiogenesis and metastasis of many cancers includ-
ing GC, has been previously discussed.11,12 Moreover, inflammatory 
cytokines such as interleukin (IL)-1, IL-6, and tumor necrosis 
factor-alpha (TNF-α) are generally responsible for the epigenetic 
alteration of gastric epithelial cells.13 These cytokines induce the 
mediators of angiogenesis, including VEGF and IL-8, which pro-
mote angiogenesis in cancer. These mediators also promote angio-
genesis during chronic inflammation such as cardiovascular disease, 
rheumatoid arthritis, diabetic retinopathy, delayed-type hypersensi-
tivity, and asthma.14 It has been shown that VEGF-A expression is 
up-regulated in response to H. pylori infection.15 Indeed, H. pylori 
activates the c-Jun N-terminal Kinases (JNK) signaling pathway, 
which leads to transactivation of the VEGF-A promoter. VEGFs 
promote angiogenesis, which is a pathophysiological mechanism 
that can result in inflammatory and ulcerative epithelial lesions and 
malignant tumor growth and metastasis.15
To understand the role of VEGFs in the pathogenesis of H. 
pylori-related gastric abnormalities, the mRNA expression levels of 
VEGF-A and C were determined in patients with peptic ulcers or 
GC, and compared with those with non-ulcer dyspepsia (NUD).
Materials and Methods
1. Patients and sampling
Patients with dyspepsia who underwent esophagogastroduo-
denoscopy at Imam Hospital or Tooba Outpatient Clinic (Mazan-
daran University of Medical Sciences, Sari, Iran) were enrolled in 
the study. All samples were collected between January 2012 and 
December 2013. The study was approved by the ethics committee 
of Mazandaran University of Medical Sciences. Clinical history, 
demographic data, and written informed consent forms were ob-
tained from all study subjects. None of the subjects had a history of 
chronic inflammatory or autoimmune disorders or treatment with H. 
pylori eradication therapy, nor did they receive any non-steroidal 
anti-inflammatory drugs for 2 weeks prior to enrollment. Among 
patients with GC, none had undergone surgery, radiotherapy, or 
chemotherapy, or received any other medical intervention before 
sample donation.
Based on the endoscopic and histopathological assessments, the 
patient samples were divided into three groups: NUD, PUD, and 
GC. The histological grade of the gastric tumors was determined 
based on the state of differentiation. PUD was defined as a circum-
scribed mucosal break (＞5 mm in diameter, with apparent depth) 
in the stomach or duodenum, covered with exudates. H. pylori 
infection was diagnosed by histopathological examination (includ-
ing Giemsa staining) and a positive result on the rapid urease test 
performed on at least one additional biopsy sample. Patients were 
considered H. pylori positive if the results of one or both diagnostic 
methods were positive, and H. pylori negative if the results of both 
methods were negative. Patients in NUD group were then divided 
into two groups: H. pylori positive and H. pylori negative. Tissue 
samples were obtained from all patients during endoscopy and pre-
served in RNALater (Qiagen, Phoenix, AZ, USA).
2. RNA isolation and cDNA synthesis
Each tissue specimen was homogenized using mortar and pestle 
at room temperature. Total RNA was extracted from the dissected 
tissues using commercial RNA extraction kits (RNeasy Minikit; 
Qiagen), according to the manufacturer’s instructions. The quantity 
and quality of the extracted RNA were assessed using a nanodrop 
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, 
USA) and agarose gel electrophoresis, respectively. RNA (1 μg) was 
reverse-transcribed into complementary DNA (cDNA) using the 
RevertAidTM First-Strand cDNA Synthesis Kit (Fermentas, Pitts-
burg, PA, USA) primed with random hexamers as per the manu-
facturer’s instructions.
3. Quantitative reverse transcriptase-polymerase 
chain reaction (qRT-PCR)
VEGF-A, VEGF-C and hypoxanthine-guanine phospho-
ribosyl transferase (HGPRT, for normalization), sequences were 
obtained from the GenBank (Table 1). Primers for amplification of 
VEGF-A, VEGF-C, and HGPRT were designed using the Bea-
con designer 7 software and synthesized by TIBmol (Germany) 
(Table 1).
qRT-PCR was performed using 96 well plates (Bio-Rad Labo-
ratories Inc., Hercules, CA, USA) in a volume of 20 μl containing 
